GO:0050321 tau-protein kinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050321 tau-protein kinase activity describes the catalysis of ATP-dependent phosphorylation of tau protein on serine and threonine residues, producing ADP and O-phospho-tau.
• Tau-protein kinase I (TPK I), now recognized as glycogen synthase kinase-3 beta (GSK3B), was originally identified as a key enzyme converting normal tau into an Alzheimer's disease-like paired helical filament component.
• Tau phosphorylation by TPK I is essential for amyloid beta-protein-induced neurotoxicity, linking this activity directly to Alzheimer's disease pathogenesis.
• Multiple kinases contribute to tau-protein kinase activity, including GSK3B, CDK5, and others, and their interplay modulates tau phosphorylation in physiological and pathological states.
• Dysregulated tau-protein kinase activity is a central mechanism in tauopathies such as Alzheimer's disease, making it a prime therapeutic target.
• CRISPR-based knockout, point-mutation, and knock-in models enable precise dissection of tau-protein kinase genes and their roles in neurodegeneration.
Description
Tau-protein kinase activity (GO:0050321) is a molecular function defined as the catalysis of the reaction ATP + tau-protein = ADP + O-phospho-tau-protein on serine and threonine residues. This activity is central to the regulation of tau, a microtubule-associated protein that stabilizes neuronal microtubules. Under pathological conditions, hyperphosphorylation of tau by tau-protein kinases leads to the formation of paired helical filaments (PHFs), a hallmark of Alzheimer's disease and other tauopathies. The term encompasses several enzymes historically named tau-protein kinase I (TPK I) and tau-protein kinase II (TPK II), which correspond to glycogen synthase kinase-3 beta (GSK3B) and cyclin-dependent kinase 5 (CDK5), respectively. Research into GO:0050321 has been instrumental in understanding how amyloid beta-protein triggers neurotoxicity through tau phosphorylation. Moreover, the modulation of tau-protein kinase activity by upstream signals and its impact on neuronal function make it a critical area of study for neurodegenerative disease mechanisms and therapeutic development.
tau-protein kinase activity At A Glance
| GO ID | GO:0050321 |
|---|---|
| GO term | tau-protein kinase activity |
| Ontology | molecular_function |
| Synonym | ATP:tau-protein O-phosphotransferase activity; brain protein kinase PK40erk activity; cdk5/p20; CDK5/p23; glycogen synthase kinase-3beta activity; GSK; protein tau kinase activity; STK31; tau kinase activity; tau protein kinase activity; [Tau protein] kinase activity; tau-protein kinase I activity; tau-protein kinase II activity; tau-tubulin kinase activity; TPK; TPK I; TPK II; TTK |
| Major function | Catalysis of ATP-dependent phosphorylation of tau protein on serine and threonine residues, producing ADP and O-phospho-tau-protein. |
| Reaction | ATP + tau-protein = ADP + O-phospho-tau-protein |
| Substrates | Tau protein (MAPT), ATP |
| Products | O-phospho-tau-protein, ADP |
| Representative kinases | GSK3B (TPK I), CDK5 (TPK II), and others |
What Is GO:0050321?
In our own words, tau-protein kinase activity (GO:0050321) is the enzymatic function by which a protein kinase transfers a phosphate group from ATP to the tau protein, specifically onto serine or threonine amino acid residues. This post-translational modification converts normal tau into O-phospho-tau, which can alter tau's ability to bind and stabilize microtubules. The activity is attributed to multiple kinases, including GSK3B (TPK I) and CDK5 (TPK II), and is a key step in the pathological hyperphosphorylation of tau observed in Alzheimer's disease and related disorders.
Why Is tau-protein kinase activity Important in Cell Biology?
Tau-protein kinase activity is critically important because it directly regulates tau function and is a primary driver of tau pathology in Alzheimer's disease and other neurodegenerative disorders. The phosphorylation of tau by kinases such as GSK3B and CDK5 disrupts microtubule stability and promotes the formation of neurofibrillary tangles, a hallmark of tauopathies. Moreover, amyloid beta-protein-induced neurotoxicity requires tau-protein kinase I activity, establishing a mechanistic link between amyloid plaques and tau tangles. Understanding this activity is therefore essential for developing therapeutic strategies that target tau phosphorylation in Alzheimer's disease and related conditions.
• Central to the formation of paired helical filaments and neurofibrillary tangles in Alzheimer's disease.
• Required for amyloid beta-protein-induced neurotoxicity in neurons.
• Regulates microtubule stability through tau phosphorylation.
• Involved in normal brain development and neuronal function.
• Dysregulated in tauopathies including frontotemporal dementia and progressive supranuclear palsy.
• A target for therapeutic intervention in Alzheimer's disease.
• Modulated by upstream signaling pathways such as corticotropin-releasing factor receptors.
• Multiple kinases contribute to tau phosphorylation, offering diverse targets for research.
• Key to understanding the interplay between amyloid and tau pathologies.
• Provides a basis for CRISPR-based disease modeling and drug discovery.
What Happens During tau-protein kinase activity?
Substrate recognition and binding
In simple terms: The kinase first grabs onto the tau protein at specific sites.
Tau-protein kinases recognize tau protein through specific serine and threonine residues, often in the context of priming phosphorylation or specific amino acid sequences. For example, GSK3B (TPK I) preferentially phosphorylates tau at sites primed by other kinases, while CDK5 (TPK II) can phosphorylate tau at multiple sites. This binding is a prerequisite for the subsequent catalytic transfer of phosphate.
Phosphoryl transfer
In simple terms: The kinase takes a phosphate from ATP and attaches it to tau.
Upon binding, the kinase catalyzes the transfer of the gamma-phosphate group from ATP to the hydroxyl group of a serine or threonine residue on tau, resulting in O-phospho-tau and ADP. This reaction is the defining catalytic event of GO:0050321. The phosphorylation alters tau's conformation and its interaction with microtubules.
Conformational change and aggregation
In simple terms: Phosphorylated tau changes shape and starts to clump together.
Phosphorylation of tau by TPK I converts normal tau into an Alzheimer's disease-like component that can assemble into paired helical filaments (PHFs). This conformational change is a key step in the pathological aggregation of tau, leading to neurofibrillary tangles. The activity of tau-protein kinases is thus directly linked to tau aggregation.
Modulation by upstream signals
In simple terms: Other molecules can turn the kinase activity up or down.
Tau-protein kinase activity is modulated by various upstream factors. For instance, corticotropin-releasing factor receptors can modulate lipopolysaccharide-induced tau phosphorylation and kinase activity, though they do not mediate it directly. Additionally, kinase-kinase interactions can regulate the activity and substrate specificity of tau kinases. This regulation ensures tight control of tau phosphorylation under normal conditions.
Key Genes Involved in GO:0050321 tau-protein kinase activity
The following genes encode kinases or related proteins that contribute to tau-protein kinase activity (GO:0050321) or regulate tau phosphorylation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GSK3B | Glycogen synthase kinase-3 beta; also known as tau-protein kinase I (TPK I); phosphorylates tau on serine/threonine residues | Key kinase in tau hyperphosphorylation and Alzheimer's disease; target for inhibitors |
| CDK5 | Cyclin-dependent kinase 5; also known as tau-protein kinase II (TPK II); phosphorylates tau | Involved in neurodevelopment and neurodegeneration; requires p35/p25 activators |
| MAPT | Microtubule-associated protein tau; substrate of tau-protein kinases | Mutations cause frontotemporal dementia; central to tauopathies |
| FYN | Src family kinase; can phosphorylate tau and modulate GSK3B activity | Implicated in Alzheimer's disease and tau pathology |
| DYRK1A | Dual-specificity tyrosine phosphorylation-regulated kinase 1A; phosphorylates tau | Associated with Down syndrome and Alzheimer's disease |
| MARK1 | Microtubule affinity-regulating kinase 1; phosphorylates tau | Regulates microtubule stability; linked to tau pathology |
| CAMK2A | Calcium/calmodulin-dependent protein kinase II alpha; can phosphorylate tau | Involved in synaptic plasticity and tau phosphorylation |
| CSNK1D | Casein kinase 1 delta; phosphorylates tau and primes for GSK3B | Modulates tau phosphorylation and circadian rhythms |
| CSNK1E | Casein kinase 1 epsilon; phosphorylates tau | Similar to CSNK1D; potential therapeutic target |
| TTBK1 | Tau-tubulin kinase 1; phosphorylates tau | Specifically phosphorylates tau at multiple sites; linked to neurodegeneration |
| TTBK2 | Tau-tubulin kinase 2; phosphorylates tau | Involved in ciliogenesis and tau phosphorylation |
| PDPK1 | 3-phosphoinositide dependent protein kinase-1; activates GSK3B and other kinases | Upstream regulator of tau kinases |
| AKT1 | Protein kinase B; phosphorylates GSK3B and inhibits its activity | Modulates tau phosphorylation via GSK3B inhibition |
| PPP1CA | Protein phosphatase 1 catalytic subunit alpha; dephosphorylates tau | Counteracts tau kinase activity; balance is critical |
| PPP2CA | Protein phosphatase 2 catalytic subunit alpha; dephosphorylates tau | Major tau phosphatase; dysfunction leads to hyperphosphorylation |
| PIN1 | Peptidyl-prolyl cis/trans isomerase; regulates tau phosphorylation | Influences tau conformation and aggregation |
| TP53 | Tumor protein p53; can modulate tau phosphorylation pathways | Links cell cycle and neurodegeneration |
| MAPK1 | Mitogen-activated protein kinase 1; can phosphorylate tau | Involved in stress responses and tau phosphorylation |
How Is tau-protein kinase activity Regulated?
Tau-protein kinase activity is regulated at multiple levels. Upstream signaling pathways, such as those involving corticotropin-releasing factor receptors, can modulate kinase activity in response to inflammatory stimuli like lipopolysaccharide. Kinase-kinase interactions also play a role in modulating tau phosphorylation; for example, the interaction between GSK3B and other kinases can alter substrate specificity and activity. Additionally, phosphatases such as PPP1CA and PPP2CA counteract kinase activity by dephosphorylating tau, maintaining a dynamic balance. Dysregulation of this balance leads to hyperphosphorylation and tau pathology.
tau-protein kinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GSK3B | Alzheimer's disease; tau hyperphosphorylation | Knockout or point-mutation in neuronal cell lines; knock-in of constitutively active GSK3B |
| CDK5 | Alzheimer's disease; neurodevelopment | Knockout in primary neurons; overexpression of p25 activator |
| MAPT | Frontotemporal dementia; tauopathies | Knock-in of human mutant tau (e.g., P301L) in mice or cells |
| FYN | Alzheimer's disease; tau phosphorylation | Knockout models to assess tau phosphorylation and memory |
| TTBK1 | Tauopathies; neurodegeneration | Knockout or kinase-dead knock-in in cell and animal models |
Alzheimer's disease
Alzheimer's disease is the most common tauopathy, characterized by amyloid beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau. Tau-protein kinase I (GSK3B) activity is essential for amyloid beta-protein-induced neurotoxicity, and its inhibition protects against tau pathology. Hyperphosphorylation of tau by GSK3B and CDK5 leads to the formation of paired helical filaments, a key step in tangle formation. Therefore, tau-protein kinase activity is a central therapeutic target in Alzheimer's disease.
Frontotemporal dementia and other tauopathies
Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is caused by mutations in the MAPT gene, which increase tau's susceptibility to phosphorylation and aggregation. Tau-protein kinases such as GSK3B and CDK5 contribute to the pathological phosphorylation of mutant tau. Other tauopathies, including progressive supranuclear palsy and corticobasal degeneration, also feature abnormal tau phosphorylation. Targeting tau-protein kinase activity may offer therapeutic benefits across these disorders.
Neuroinflammation and tau pathology
Neuroinflammation can modulate tau phosphorylation through tau-protein kinase activity. Lipopolysaccharide-induced inflammation increases tau phosphorylation and kinase activity, an effect that is modulated by corticotropin-releasing factor receptors. This link suggests that inflammatory processes in the brain may exacerbate tau pathology by activating tau kinases, providing a rationale for anti-inflammatory strategies in tauopathies.
From tau-protein kinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GSK3B reduce tau phosphorylation? | GSK3B knockout cell line (e.g., SH-SY5Y) or conditional knockout mouse |
| How does a disease-associated mutation in MAPT affect tau phosphorylation? | Knock-in of mutant MAPT (e.g., P301L) in human iPSCs or cell lines |
| Can a kinase inhibitor block tau-protein kinase activity? | Overexpression of GSK3B or CDK5 in cell lines followed by inhibitor treatment |
| What is the interactome of tau-protein kinases? | Tagged knock-in of GSK3B or CDK5 with FLAG/HA for immunoprecipitation |
| Does CDK5 hyperactivation cause tau pathology? | Overexpression of p25 in primary neurons or transgenic mice |
| Which genes modulate tau phosphorylation in a genome-wide screen? | CRISPR library screening in tau-expressing cell lines |
How to Study the tau-protein kinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| In vitro kinase assay | Phosphorylation of tau by specific kinases | Validation of kinase activity and inhibitor testing |
| Phospho-specific Western blot | Levels of tau phosphorylated at specific sites | Assessment of kinase pathway activation in cells |
| Mass spectrometry | Global tau phosphorylation sites and stoichiometry | Mapping kinase targets and crosstalk |
| CRISPR knockout screen | Genes required for tau phosphorylation | Discovery of novel regulators of tau-protein kinase activity |
| Live-cell imaging | Real-time tau aggregation and localization | Studying dynamics of tau phosphorylation and aggregation |
| Immunoprecipitation | Protein-protein interactions of tau kinases | Identifying kinase complexes and substrates |
| Kinase inhibitor profiling | Selectivity and potency of inhibitors | Drug discovery for tauopathies |
Kinase activity assays
In vitro kinase assays using recombinant tau and candidate kinases (e.g., GSK3B, CDK5) are standard for measuring tau-protein kinase activity. These assays typically use ATP and detect phosphorylated tau by Western blot with phospho-specific antibodies or by mass spectrometry. Such assays are essential for validating kinase inhibitors and understanding substrate specificity.
Phospho-proteomics
Mass spectrometry-based phospho-proteomics allows global mapping of tau phosphorylation sites after kinase activation or inhibition. This approach can identify novel sites phosphorylated by tau-protein kinases and quantify changes in response to genetic or pharmacological perturbations. It is particularly useful for studying crosstalk between kinases.
CRISPR-based genetic screens
CRISPR knockout or activation screens can identify genes that regulate tau phosphorylation. By using tau phosphorylation as a readout (e.g., immunofluorescence or reporter assays), researchers can discover novel kinases, phosphatases, or regulatory proteins that modulate GO:0050321 activity. These screens are powerful for unbiased discovery.
Live-cell imaging of tau aggregation
Fluorescently tagged tau (e.g., GFP-tau) expressed in cells can be used to monitor tau phosphorylation and aggregation in real time. This method reveals how kinase activity influences tau dynamics and aggregation propensity. It is often combined with kinase inhibitors or genetic manipulation.
How CRISPR Can Be Used to Study GO:0050321 tau-protein kinase activity
Knockout
CRISPR knockout of tau-protein kinase genes such as GSK3B or CDK5 in cell lines or primary neurons can abolish specific kinase activities, allowing researchers to determine their contribution to tau phosphorylation and neurotoxicity. For example, GSK3B knockout reduces tau phosphorylation and protects against amyloid beta-induced toxicity. Knockout models are essential for target validation.
Point Mutation
Introducing point mutations in kinase genes (e.g., kinase-dead mutations in GSK3B or CDK5) via CRISPR can dissect catalytic activity from scaffolding functions. Such models help clarify whether tau phosphorylation is solely responsible for observed phenotypes. Point mutations in MAPT (e.g., P301L) can also model disease-associated tau variants.
Knock-in
Knock-in of human mutant tau (e.g., P301L, A152T) into cell lines or animal models using CRISPR allows study of tau phosphorylation in a disease-relevant context. Tagged knock-in of kinases (e.g., HA-GSK3B) enables tracking of endogenous protein expression and interactions. These models are valuable for drug testing.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of tau kinases such as GSK3B or CDK5 can induce hyperphosphorylation of tau and model tau pathology in vitro. Overexpression of p25, a CDK5 activator, leads to tau hyperphosphorylation and neurodegeneration. These systems are useful for screening inhibitors.
How EDITGENE Supports tau-protein kinase activity Research
Researchers studying tau-protein kinase activity-related genes often need to determine whether a candidate gene is causally involved in tau phosphorylation, neurotoxicity, or disease progression. Precise genetic models are essential to move from correlation to causation. EDITGENE provides a comprehensive suite of CRISPR-based services to support such investigations, from gene knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for tau-protein kinase activity research.
Frequently Asked Questions About tau-protein kinase activity
What is tau-protein kinase activity?
Tau-protein kinase activity (GO:0050321) is the enzymatic function that catalyzes the phosphorylation of tau protein on serine and threonine residues using ATP, producing ADP and O-phospho-tau.
What genes are involved in tau-protein kinase activity?
Key genes include GSK3B (tau-protein kinase I), CDK5 (tau-protein kinase II), MAPT (the substrate tau), and others such as FYN, DYRK1A, and TTBK1.
How is tau-protein kinase activity linked to Alzheimer's disease?
Hyperactivation of tau kinases like GSK3B leads to tau hyperphosphorylation, paired helical filament formation, and neurofibrillary tangles, which are hallmarks of Alzheimer's disease.
What is the role of GSK3B in tau phosphorylation?
GSK3B, also known as tau-protein kinase I, phosphorylates tau at multiple serine/threonine residues and is essential for amyloid beta-induced neurotoxicity.
Can CRISPR be used to study tau-protein kinase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of tau kinase genes to study their roles in tau phosphorylation and disease.
What are the main tau kinases?
The main tau kinases include GSK3B (TPK I), CDK5 (TPK II), and others such as DYRK1A, MARK1, and TTBK1.
How is tau-protein kinase activity measured?
It is commonly measured using in vitro kinase assays with recombinant tau and ATP, followed by detection of phospho-tau by Western blot or mass spectrometry.
What diseases are associated with tau-protein kinase activity?
Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, and other tauopathies are associated with dysregulated tau phosphorylation.
What is the difference between TPK I and TPK II?
TPK I corresponds to GSK3B, while TPK II corresponds to CDK5; both phosphorylate tau but have distinct regulatory mechanisms and substrate preferences.
How can I model tau-protein kinase activity in the lab?
You can use CRISPR knockout or overexpression of kinases like GSK3B or CDK5 in neuronal cell lines, or knock-in of mutant tau, combined with kinase assays and imaging.
Conclusion
Tau-protein kinase activity (GO:0050321) is a fundamental molecular function that drives tau phosphorylation and is intimately linked to the pathogenesis of Alzheimer's disease and other tauopathies. The activity of kinases such as GSK3B and CDK5, and their regulation by upstream signals, determines the balance between normal tau function and pathological aggregation. Understanding this activity through CRISPR-based models and advanced biochemical assays offers promising avenues for therapeutic intervention. Continued research into the mechanisms and regulation of tau-protein kinases will be crucial for developing effective treatments for neurodegenerative diseases.
References
- 1. Takashima A et al.. 1993. Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity.. Proc Natl Acad Sci U S A 90(16):7789-93 PMID: 8356085
- 2. Hashiguchi M et al.. 2013. Kinase-kinase interaction and modulation of tau phosphorylation.. Int Rev Cell Mol Biol 300:121-60 PMID: 23273861
- 3. Roe AD et al.. 2011. Lipopolysaccharide-induced tau phosphorylation and kinase activity--modulation, but not mediation, by corticotropin-releasing factor receptors.. Eur J Neurosci 34(3):448-56 PMID: 21722209
- 4. Mukai F et al.. 2002. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta.. J Neurochem 81(5):1073-83 PMID: 12065620
- 5. Martin L et al.. 2013. Tau protein kinases: involvement in Alzheimer's disease.. Ageing Res Rev 12(1):289-309 PMID: 22742992
- 6. Ishiguro K et al.. 1992. Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments.. J Biol Chem 267(15):10897-901 PMID: 1587865
- 7. Ishiguro K. 1998. [Involvement of tau protein kinase in amyloid-beta-induced neurodegeneration].. Rinsho Byori 46(10):1003-7 PMID: 9816911
- 8. Iqbal K et al.. 2014. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease.. Expert Opin Ther Targets 18(3):307-18 PMID: 24387228
